Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAdvisors Asset Management, Inc.
Latest Disclosed Ownership24,300 shares
Latest Disclosed Value $ 10,850,922
Advisors Asset Management, Inc. reports 1.67% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Advisors Asset Management, Inc. filed a 13F-HR form disclosing ownership of 24,300 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $10,850,922 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 24,713 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -1.67% during the quarter. The current value of the position is $10,857,969 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,300 -413 -1.67 10,851 -3.15 0.1802
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,713 -1,213 -4.68 11,204 10.34 0.1881
2025-11-06 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,926 841 3.35 10,154 -9.08 0.1723
2025-08-12 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,085 -2,659 -9.58 11,168 -16.97 0.1999
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,744 132 0.48 13,451 20.96 0.2527
2025-02-10 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,612 1,145 4.33 11,119 -9.67 0.2048
2024-11-08 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,467 3,359 14.54 12,309 13.65 0.2261
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,108 1,724 8.06 10,831 21.18 0.2112
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,384 3,656 20.62 8,939 23.92 0.1718
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,728 252 1.44 7,213 18.69 0.1473
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,476 1,850 11.84 6,077 10.53 0.1311
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,626 2,131 15.79 5,499 29.33 0.1123
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,495 1,709 14.50 4,252 24.92 0.0865
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,786 -413 -3.39 3,404 -3.65 0.0701
2022-11-08 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,199 1,333 12.27 3,532 15.35 0.0743
2022-08-08 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,866 -5,000 -31.51 3,062 -26.06 0.0581
2022-05-17 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,866 -5,376 -25.31 4,141 -11.23 0.0638
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,242 -4,458 -17.35 4,665 0.06 0.0666
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,700 -1,967 -7.11 4,662 -16.42 0.0709
2021-07-30 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,667 -3,092 -10.05 5,578 -15.61 0.0823
2021-05-07 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,759 2,604 9.25 6,610 -0.66 0.1028
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,155 3,284 13.20 6,654 -1.68 0.1100
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,871 705 2.92 6,768 -3.53 0.1251
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,166 4,342 21.90 7,016 48.74 0.1366
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,824 2,866 16.90 4,717 27.04 0.1122
2020-05-20 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 16,958 1,473 9.51 3,713 41.56 0.0651
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,958 1,473 3,713 32,863.5606
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,485 -1,022 -6.19 2,623 -13.35 0.0483
2019-11-14 2019-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 16,507 -3,612 -17.95 3,027 -18.21 0.0546
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,507 -3,612 3,027
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 20,119 2,569 14.64 3,701 27.27 0.0659
2019-02-06 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 17,550 3,458 24.54 2,908 7.07 0.0585
2019-01-31 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,550 3,458 2,908
2018-11-15 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,092 -1,342 -8.70 2,716 3.55 0.0444
2018-08-22 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 15,434 2,694 21.15 2,623 24.02 0.0446
2018-08-15 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,966 6,226 2,623
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,740 -640 -4.78 2,115 5.49 0.0354
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,380 149 1.13 2,005 -0.35 0.0330
2017-11-07 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,231 -1,762 -11.75 2,012 4.14 0.0337
2017-08-02 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,993 -850 -5.37 1,932 11.55 0.0323
2017-05-02 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,843 -12,779 -44.65 1,732 -30.61 0.0290
2016-10-31 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,622 -6,111 -17.59 2,496 -16.47 0.0409
2016-08-08 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,733 -1,636 -4.50 2,988 3.36 0.0484
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,369 -8,642 -19.20 2,891 -48.96 0.0481
2016-02-10 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 45,011 -1,917 -4.08 5,664 15.90 0.0899
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 46,928 5,974 14.59 4,887 -3.36 0.0779
2015-08-11 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 40,954 3,743 10.06 5,057 15.19 0.0694
2015-05-13 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,211 9,261 33.13 4,390 32.23 0.0585
2015-02-05 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,950 4,906 21.29 3,320 28.28 0.0445
2014-11-13 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,044 9,128 65.59 2,588 96.36 0.0357
2014-08-14 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,916 7,668 122.73 1,318 198.19 0.0183
2014-05-15 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,248 4,948 380.62 442 355.67 0.0067
2014-02-03 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 100 8.33 97 6.59 0.0016
2013-11-15 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,200 -5,800 -82.86 91 -83.72 0.0016
2013-08-14 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,000 7,000 559 0.0106
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.